CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
Abstract
Glioblastoma (GBM) is a devastating primary brain tumor with a highly immunosuppressive tumor microenvironment, and treatment with oncolytic viruses (OVs) has emerged as a promising strategy for these tumors. Our group constructed a new OV named Delta-24-ACT, which was based on the Delta-24-RGD platform armed with 4-1BB ligand (4-1BBL). In this study, we evaluated the antitumor effect of Delta-24-ACT alone or in combination with an immune checkpoint inhibitor (ICI) in preclinical models of glioma.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 01, 2021
- Source ID
- 10.1136/jitc-2021-002644
Entities
People
- Ana Patino Garcia
- Candelaria Gomez-Manzano
- Daniel de la Nava
- Dolores Hambardzumyan
- Guillermo Herrador
- Hong Jiang
- Iker Ausejo
- Jaime Gállego Pérez-Larraya
- Juan Fueyo
- Lucia Marrodan
- Marc Garcia-Moure
- Marisol Gonzalez-Huarriz
- Marta M Alonso
- Marta Zalacain
- Montserrat Puigdelloses
- Naiara Martínez-vélez
- Sandra Hervás-stubbs
- Sara Labiano
- Virginia Laspidea
- Zhihong Chen
Organizations
- United States Department of Defense